Embed Size (px)
Citation preview
CREATED TO ACCELERATE BREAKTHROUGHS IN DISEASE DETECTION, PREVENTION AND TREATMENT
Is biobanking a good investment ?
EBIC (2005-2008)http://www.phac-aspc.gc.ca/publicat/ebic-femc/2005-2008/assets/pdf/ebic-femc-2005-2008-eng.pdf
11.7
11.45.8
5.5
5.1
Direct costs in billion dollars
CardiovascularNeuropsychiatric Musculoskeletal Digestive Injuries
The Global Burden of Disease Study
The economic impact of disease
http://blog-epi.grants.cancer.gov/2013/04/15/combined-environmental-exposures/
HEALTH VS. DISEASEEXPOSOME
GENOME
Genes + Environment = Health
MISSION To facilitate innovation and research projects, while ensuring the longitudinal mandate of the cohort.
MANDATE Advance and improve knowledge of population health.
1. Facilitate the emergence of new projects and foster collaborations. 2. Reduce research costs. 3. Contribute to improve the quality of care and to provide data based evidence for prevention of disease 4. Enable tailored medicine
Why CARTaGENE ?
• Projet conçu par Claude Laberge, MD, Ph.D
• Étude pilote menée en 2009• Phase A: 20 000 participants âgés entre
40-69 ans – mesures physiques et cliniques + questionnaires
+ échantillons (juillet 2009-Oct 2010)
• Phase B (Jan 2014-Jan 2015) 22 000 nouveaux participants
– Mesures cliniques + questionnaires + échantillons (Jan 2013-Mars 2015)
• Représentation régionale de 70% de la population québécoise
• Premier suivi prévu pour 2016
42 000
Phas
e A
Phas
e B
The CARTaGENE project
> 300 000 participants Blood samples> 140 000 Physical measures> 90 000
$140 million invested
Go big or go home
Recruitment Data and Sample Management Access
Broad, general informed consent
The CARTaGENE project
Diabete
s
Thyroi
d diso
rder
High ch
oleste
rol
High B
P
Angina
Stroke MI
COPD
Asthma
Renal
failur
e
Kidney
ston
es
Kidney
infec
tion
Osteoa
rthriti
s
Rheum
atoid
arthri
tis
Osteop
orosis
Glauco
ma
Catarac
ts
Macula
r deg
enera
tion
Cirrhos
is
Chronic
hepa
titis
Choles
cysti
tis
Acid re
flux/u
lcer
IBS
Polyps
Divertic
ulitis
Crohns
Eczem
a
Psoria
sis SLE
Major d
epres
sion
Epilep
sy
Migrain
es MS
Parkins
on’s
Schizo
phren
ia
All can
cers
0
1,000
2,000
3,000
4,000
5,000
6,000
Num
ber o
f par
ticip
ants
Awadalla P., Boileau C., 2012
Reported disease at baseline
The CARTaGENE project
VOLETGÉNOMIQUE
VOLET LONGITUDINAL
VOLETFAMILLE
VOLETENVIRONNEMENT
CARTaGENEMaintien de la biobanque
Services d’AccèsRecherche
MARS 2017
MARS 2020
SECTEURS D’ACTIVITÉS
Access
Open ACCESSConditions• Project on human health• Local Ethics approval• Enough funds to carry out research and to pay for fees• Any recognized researcher is admissible from private and from
the public sector. No insurance companies allowed.
Scientific DirectorCatherine Boileau – Epidemiology
Anne-Monique Nuyt Yves Payette – Data manager
Sébastien Jacquemont Nolwenn Noisel – Operations
Thibault de Maillard - bioinformatics
Gabrielle Thauvette - analyst
Executive Geneviève David - Communications
Alexandra Obadia – CEO Maria Barone – Human ressources and finance
Charles Rivard – finance analyst
